Down-regulation of MDR1 gene expression by CRISPRi to enhance the sensitivity of lung adenocarcinoma A549/DDP cells to cisplatin

doi:10.12047/j.cjap.6342.2022.109

Abstract

Abstract: Objective: To investigate the effects of down-regulating MDR1 gene expression by CRISPRi on enhancing the sensitivity of lung adenocarcinoma A549/DDP cells to cisplatin. Methods: The potential CRISPRi interference sites on the MDR1 gene promoter were predicted by bioinformatics software, and the interference fragments were designed and constructed. The mRNA and protein expression levels of MDR1 gene in each group of cells were detected by qRT-PCR and Western blot methods, and the recombinant vectors with high interference efficiency were screened. Human lung cancer A549/DDP cells were divided into three groups: A549/DDP, Scrambed and sgRNA-MDR1-1, with three multiple holes in each group. After each vector was transfected into the cells for 48 h, the efflux of cells in each group was detected by flow cytometry, the IC₅₀ value of cells in each group was detected by MTT method, and the cell morphology of cells treated with cisplatin was observed under laser confocal microscope. Results: After sequencing and comparison, two kinds of CRISPRi recombinant vectors interfering with MDR1 gene transcription were constructed successfully. After transfection of A549/DDP cells, the mRNA and protein levels of MDR1 gene in all transfection groups were decreased significantly (P＜ 0.01). Among them, the interference efficiency of sgRNA-MDR1-1 was the highest, and the interference efficiency of mRNA and protein was 60% and 51%, respectively. After transfection of sgRNA-MDR1-1 vector, compared with the control group, the efflux ability of cells was decreased (P＜0.01), the IC₅₀ value of cells to cisplatin was decreased significantly (P＜0.01), and the intracellular chromatin gathered and marginalized, and apoptotic bodies appeared. Conclusion: CRISPRi interference with MDR1 gene in drug-resistant A549/DDP cells can significantly enhance the sensitivity to cisplatin.

Key words: CRISPRi, MDR1 gene, drug sensitivity, lung adenocarcinoma A549/DDP cell, cell culture

CLC Number:

Q291

LIU Kai, SUN Xin-di, ZHANG Wei-wei, YANG Qing-zhu, HUANG Xin, SHAO Shu-li. Down-regulation of MDR1 gene expression by CRISPRi to enhance the sensitivity of lung adenocarcinoma A549/DDP cells to cisplatin[J]. CJAP, 2022, 38(5): 590-594.

References

[1] Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021[J]. CA-Cancer J Clin, 2021, 71(1): 7-33.
[2] 胡俊, 蓝冰. 肺癌患者化疗期症状群管理的难点及对策[J]. 当代护士(中旬刊), 2021, 28(10): 71-74.
[3] Kong FB, Deng QM, Deng HQ, et al. Siva-1 regulates multidrug resistance of gastric cancer by targeting MDR1 and MRP1 via the NF-KB pathway[J]. Mol Med Rep, 2020, 22(2): 1558-1566.
[4] Fung KL, Gottesman MM. A synonymous polymorphism in a common MDR1 (ABCB1) haplotype shapes protein function[J]. Biochim Biophys Acta, 2009, 1794(5): 860-871.
[5] 刘芳, 宋玉芳, 张学辉, 等. 多药耐药基因表达与上皮性卵巢癌化疗耐药的相关性[J]. 中国医刊, 2021, 56(5): 561-564.
[6] 任爱华, 刘婉, 王大伟. 基于CRISPR/Cas9技术敲除PD-L1对非小细胞肺癌PC-9/T790M细胞吉非替尼耐药敏感性的影响[J]. 吉林大学学报(医学版), 2021, 47(2): 292-298.
[7] Yoshida M, Yokota E, Sakuma T, et al. Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma[J]. Oncotarget, 2018, 9(49): 29220-29232.
[8] Liu SJ, Malatesta M, Lien BV, et al. CRISPRi-based radiation modifier screen identifies long non-coding RNA therapeutic targets in glioma[J]. Genome Biol, 2020, 21(1): 83.
[9] 刘宗超, 李哲轩, 张阳, 等. 2020全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志, 2021, 7(2): 1-14.
[10] 彭钧, 鲍方, 李小月, 等. MDR1、PEDF、LRP在宫颈癌中的表达及意义[J]. 中国现代医学杂志, 2021, 31(13): 11-16.
[11] Liu WT, Lo YL, Hsu C, et al. CS-PEI/Beclin-siRNA downregulate multidrug resistance proteins and increase paclitaxel therapeutic efficacy against NSCLC[J]. Mol Ther- Nucl Acids, 2019, 17: 477-490.
[12] 陈明军, 陈奇, 周月鹏. Bmi-1调控非小细胞肺癌细胞对顺铂的敏感性研究[J]. 医学研究生学报, 2019, 32(7): 710-714.
[13] Yuan Z, Liang X, Zhan Y, et al. Targeting CD133 reverses drug-resistance via the AKT/NF-κB/MDR1 pathway in colorectal cancer[J]. Brit J Cancer, 2020, 122(9): 1-12.
[14] O'Connell MR, Oakes BL, Sternberg SH, et al. Programmable RNA recognition and cleavage by CRISPR/Cas9[J]. Nature, 2014, 516(7530): 263-266.
[15] 田开仁, 薛二淑, 宋倩倩, 等. CRISPR-dCas9调控基因转录的研究进展[J]. 中国生物工程杂志, 2018, 38(7): 94-101.
[16] 窦娜, 李春晓, 王婷, 等. MTA1通过上调CK19促进结肠癌细胞HCT116的侵袭[J]. 癌症进展, 2019, 17(10): 1147-1151.
[17] 于鹏, 尹天翔, 罗彩云. 盐酸罗哌卡因对骨肉瘤细胞增殖、侵袭、凋亡的影响及其机制[J]. 中国应用生理学杂志, 2021, 37(6): 654-659.
[18] Liao X, Gao Y, Sun L, et al. Rosmarinic acid reverses non-small cell lung cancer cisplatin resistance by activating the MAPK signaling pathway[J]. Phytother Res, 2020, 34(5): 1142-1153.
[19] 苏建伟, 周喜汉, 叶颖霞. 苦参素复合长春新碱对HCT-8/VCR细胞耐药性的影响及其机制[J]. 中国应用生理学杂志, 2020, 36(4): 350-353.